---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-236862"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2026-05-22T20:05:44+00:00"
generated_at: "2026-05-22T21:12:07.552220+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics stockholders approve doubling authorized shares to 600M and elect directors

## Summary
- Katina Dorton (19.7M for) and R. Keith Woods (23.3M for) elected as Class II directors for three-year terms.
- Deloitte & Touche ratified as independent auditor for fiscal year ending Dec 31, 2026 (38.5M for).
- Amendment to increase authorized voting common stock from 300M to 600M shares approved (35.9M for).
- Proposal to adjourn meeting not needed; quorum and sufficient proxies already present.
- Annual meeting held on May 20, 2026; no other matters submitted to vote.

## SEC filing metadata
- accession: 0001193125-26-236862
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2026-05-22T20:05:44+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312526236862/0001193125-26-236862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312526236862/d43301d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-236862
- JSON: https://secwatch.observer/filing/0001193125-26-236862.json
- Plain text: https://secwatch.observer/filing/0001193125-26-236862.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.